Mesoblast Limited's Strong Cash Position Enables Execution of Late-Stage Clinical Trials
8/29/2013 9:57:51 AM
NEW YORK and MELBOURNE, Australia, Aug. 29, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company, Mesoblast Limited (ASX:MSB) (OTC ADR:MBLTY), today provided its full year financial results. The Company stated that it had total funds of $315.3 million at 30 June 2013, compared with $205.6 million in the financial year ended 2012. Mesoblast recorded total revenue and other income of $34.7 million (2012: $38.3m) and a loss after tax of $61.7 million (2012:$71.1m) in the 2013 financial year.
Help employers find you! Check out all the jobs and post your resume.
comments powered by